The FDA is moving to accelerate early-stage drug development in the US while tightening oversight where trials are conducted abroad. The agency launched an Expedited Investigational New Drug (IND) Pilot as part of “Operation Trialblazer,” inviting up to 10 qualified research institutions to support sponsors with rolling reviews for first-in-human applications. In parallel, the FDA said it will increase resources for foreign bioresearch monitoring (BIMO) inspections and update risk-based criteria for which overseas clinical sites to audit. The agency cited challenges with unannounced audits abroad, concerns about host-country regulatory capacity, and questions over whether results generalize to US patients—particularly in multiregional trials with limited US enrollment. Together, the initiatives signal a coordinated push to keep more Phase 1 timelines inside the US regulatory system, while also raising the compliance bar for data generated outside it. Sponsors with China- and Australia-heavy early portfolios face both faster pathways at home and more scrutiny on the evidence used to support US filings.